By Sal Daher, CFA From the sixty plus angel investments I made since the early 1990s most of the value has been created among the life science companies. That’s why I’m focusing my angel investing exclusively on life science startups. I expect the coming decade to see growing opportunities for angel investors to help academic …
By Sal Daher, CFA Vedanta Biosciences announced October 5th, 2021 that its experimental therapy VE303 reduces the likelihood of recurrence of C. diff. by more than 80%. BARDA exercises $23.8 million to fund Phase 3 clinical trials starting in 2022. Heres a link to the press release: https://www.businesswire.com/news/home/20211005005154/en/PureTech-Founded-Entity-Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA
by Sal Daher, CFA Daphne Zohar is pioneering a distinctive approach to innovation in biotech that does not attract enough attention. It involves unusual openness to new ideas coupled with disciplined vetting of the ideas’ technical and commercial possibilities. She also has keen eye for talent. The results are astonishing. I know this first hand …
Cellino Biotech is mixing three disciplines: machine learning, laser physics and cell biology to create affordable treatments from your own cells. Imagine a future where you are diagnosed with a degenerative disease, such as Parksinson’s or Alzheimer’s, and within days an effective treatment, made from your own cells, is ready to be administered. That’s the …
AI + Lasers + Your Cells Is the New Formula for Personalized Medicine Read More »
We are entering the Decade of Biotech as powerful technologies begin to bear plentiful fruit. Many of these technologies will be accessible to academic founders working in shared lab spaces and funded by angel investors. Angels can invest in these early-stage biotech companies in three main ways, (1) directly on the capitalization table [the list …
The way cancer is treated is about to change. Close monitoring during treatment will become possible, telling us within days with much greater precision if a treatment is working or not. Long-term monitoring of patients in remission will also be revolutionized by making fewer biopsies necessary and detecting relapses much earlier. All these promises come …
SQZ’s successful IPO validates the vision laid out by Armon Sharei, PhD in this interview recorded two years ago. In accessible language, this genius founder explains the approach that has big strategic players excited. SQZ is the model I have in mind when I invest in biotech companies. Find out why. Armon Sharei wants to …
Coming from a family of lawyers in Italy, Laura Indolfi was an unlikely candidate to found a tech startup. Yet, her love of engineering and fascination with materials took her to the storied labs at MIT led by Elazer Edelman and Bob Langer. Her startup, PanTher Therapeutics is using off-the-shelf cancer drugs and biomaterials to …
Engineer and consultant Susan Conover’s struggle with skin cancer inspires her to apply AI to help us understand what’s going on with our skin. This determined founder has made considerable headway in building the most valuable asset an AI startup can have: a strong, proprietary data set. A fun interview with a dynamic founder. HIGHLIGHTS …
Brilliant Spanish postdoc, Carlos Castro-González, goes to MIT’s “Magic Wand” lab, and joins a superb international team to address an important medical problem. Leuko, their startup, now has a device and software that can tell when cancer patients are becoming immuno-compromised. Leuko’s product has the potential of saving 4,000 lives and $1.5 billion every year …
Carlos Castro-González, “To Save 4000 Lives a Year” Read More »
